Alkharfy Khalid M, Ahmad Ajaz, Khan Rao M A, Al-Shagha Waleed M
Department of Clinical Pharmacy, College of Pharmacy, King Saud University, PO Box 2457, Riyadh, 11451, Saudi Arabia,
Eur J Drug Metab Pharmacokinet. 2015 Sep;40(3):319-23. doi: 10.1007/s13318-014-0207-8. Epub 2014 Jun 13.
Thymoquinone (THQ), the active constituent of Nigella sativa seeds, has demonstrated some potential pharmacological activities. The present study was designed to investigate the pharmacokinetic behavior of THQ following intravenous (IV) and oral (PO) administration using an animal model. THQ was given vascularly (5 mg/kg IV) and extravascularly (20 mg/kg PO) to Vole rabbits, and blood samples were collected at predetermined time points. The concentrations of THQ in plasma were measured by a high-performance liquid chromatography, and the pharmacokinetic parameters were determined using both compartmental and non-compartmental analyses. The calculated clearance (CL) following IV administration was 7.19 ± 0.83 ml/kg/min, and the estimated volume of distribution at steady state (V ss) was 700.90 ± 55.01 ml/kg. Whereas with PO dosing, apparent CL/F value was 12.30 ± 0.30 ml/min/kg and V ss/F was 5,109.46 ± 196.08 ml/kg. These parameters were associated with an elimination half-life (T 1/2) of 63.43 ± 10.69 and 274.61 ± 8.48 min with IV and PO dosing, respectively. The calculated absorption T 1/2 was about 217 min. Compartmental analysis revealed T 1/2α of ~8.9 min and T 1/2β of ~86.6 min. The calculated absolute bioavailability of THQ was ~58 % with a lag time of ~23 min. The estimated THQ protein binding was >99 %. Therefore, THQ represents a compound with rapid elimination and relatively slower absorption following PO administration.
百里醌(THQ)是黑种草籽的活性成分,已显示出一些潜在的药理活性。本研究旨在使用动物模型研究静脉注射(IV)和口服(PO)给药后THQ的药代动力学行为。给长爪沙鼠静脉注射(5mg/kg IV)和非静脉注射(20mg/kg PO)THQ,并在预定时间点采集血样。采用高效液相色谱法测定血浆中THQ的浓度,并使用房室分析和非房室分析确定药代动力学参数。静脉注射后计算的清除率(CL)为7.19±0.83ml/kg/min,稳态分布容积(Vss)估计为700.90±55.01ml/kg。而口服给药时,表观CL/F值为12.30±0.30ml/min/kg,Vss/F为5109.46±196.08ml/kg。这些参数对应的静脉注射和口服给药的消除半衰期(T1/2)分别为63.43±10.69分钟和274.61±8.48分钟。计算得出的吸收半衰期约为217分钟。房室分析显示T1/2α约为8.9分钟,T1/2β约为86.6分钟。THQ的计算绝对生物利用度约为58%,滞后时间约为23分钟。估计THQ的蛋白结合率>99%。因此,THQ是一种消除迅速、口服给药后吸收相对较慢的化合物。